Objective: Ghrelin is the recently identified endogenous ligand for the ghrelin receptor GHS-R1a and known to regulate growth hormone secretion and appetite. Ghrelin also is a potent vasodilator and improves cardiac performance after systemic administration. Generally, the octanoyl modification on Ser 3 has been considered essential for biological activity. Recently however, cardiovascular actions of des-octanoyl ghrelin have been reported in rodents. Our aim was to investigate if ghrelin and ghrelin receptor protein are expressed within the human vasculature, to determine if des-octanoyl ghrelin, like ghrelin, is a vasodilator in human artery and to test the acute effect of ghrelin peptides on cardiac contractility. Methods: Distribution of ghrelin and ghrelin receptor was determined using standard immunocytochemistry and confocal microscopy. Ghrelin peptides were tested for vasodilator actions in human isolated arteries and their effect on cardiac contractility was investigated in human isolated paced atria. Results: Immunoreactive ghrelin was detected in endothelial cells of human arteries and veins where it localized to intracellular vesicles but not to the Weibel -Palade bodies of the regulated pathway, suggesting constitutive ghrelin production. Specific antisera detected ghrelin receptor on vascular smooth muscle cells and cardiomyocytes. Ghrelin (pD 2 = 8.60 T 0.1, E max = 55.8 T 8.9, mean T standard error of the mean) and des-octanoyl ghrelin (pD 2 = 8.8 T 0.2, E max = 54.7 T 5.3) showed comparable ( P > 0.05) endothelium independent vasodilator potency and efficacy in reversing endothelin-1 induced constriction in human artery. Neither ghrelin nor des-octanoyl ghrelin had effects on contractile force in paced atria. Conclusions: We show widespread expression of ghrelin and its cognate receptor in the human cardiovascular system with functional evidence suggesting a role for both ghrelin and the more abundant endogenous form des-octanoyl ghrelin in the paracrine regulation of vascular tone in man.
Introduction
Ghrelin, the endogenous ligand for the human G proteincoupled growth hormone secretagogue receptor (GHS-R1a, recently designated as ghrelin receptor [1] ), is a gastric peptide, cleaved from a 117 amino acid precursor with a post-translational octanoyl modification that is unique among peptide hormones [2] .
A major focus of ghrelin research is its role in neuroendocrine regulation in the central nervous system (CNS). Ghrelin and ghrelin receptors are present in discrete regions of the brain where ghrelin regulates growth hormone (GH) secretion at the hypothalamic and pituitary level by triggering secretion of growth hormone releasing hormone from hypothalamic neurons and by direct stimulation of GH release from the adenohypophysis [2, 3] . Independently of GH-secretagogue actions, ghrelin elicits orexigenic effects by increasing expression and release of neuropeptide Y and agouti-related protein, two key neuropeptides involved in the central regulation of appetite and food intake. Conversely, ghrelin inhibits the action of proopiomelanocortin, a physiological antagonist of feeding behaviour in the hypothalamus [4] .
In agreement with widespread expression of ghrelin mRNA in peripheral tissues [5] , the novel ghrelin receptor system has also been implicated in non-CNS actions including control of gastric motility and acid secretion [6] , energy homeostasis [4] and reproductive function [7] . Ghrelin shows pro-and anti-proliferative effects on tumour cells [8, 9] , modulates T-cell biology [10] and possesses regulatory properties in the cardiovascular system, both in the heart [11, 12] and vasculature [12 -18] . [ 125 I-His 9 ]-ghrelin-binding has previously been demonstrated in human heart and blood vessels using radioligand binding [19] and ghrelin was shown to possess potent endothelium independent vasodilator effects in human isolated artery [15] . In vivo studies showed a significant drop in blood pressure accompanied by increased cardiac output after ghrelin infusion in healthy volunteers [14, 18, 20] , and both in vitro and in vivo endothelium independent vasodilator effects for ghrelin have been reported in other species [15, 17, 20] . Nevertheless, meal related changes in circulating ghrelin levels, mainly derived from gastric endocrine cells [21, 22] , do not cause apparent changes in cardiovascular parameters [4, 21, 23, 24] . Since the initial characterization of the ghrelin receptor, the octanoyl group esterified onto Ser 3 of the peptide has been considered essential for biological activity [2, 25, 26] . However, peripheral effects of desoctanoyl ghrelin were recently reported in animals [27 -32] , which may have major physiological implications as more than 90% of circulating peptide lacks the octanoyl modification [2] .
We hypothesize that ghrelin is a ubiquitously expressed endothelium derived peptide in the human cardiovascular system, which if released locally can interact with specific receptors present on the underlying smooth muscle cells to cause vasodilatation. We further propose that in humans, des-octanoyl ghrelin may have peripheral functional activity comparable to ghrelin, in contrast to the CNS where the former peptide is reported to be inactive [2] . To test this hypothesis, our aims were firstly to determine the cellular localization of the ghrelin receptor and its cognate ligand in human large and small arteries and veins from representative vascular beds. We visualized immunoreactive peptide to intracellular vesicles within endothelial cells to seek evidence that the peptide might be synthesized by either the secretory or constitutive pathway [33] . Finally we compared the vascular and cardiac actions of ghrelin and des-octanoyl ghrelin on human isolated arteries and paced atrial appendage in vitro.
Methods

Tissue collection
The investigation conformed to the FDeclaration of Helsinki_. Human left ventricular and atrial myocardium and coronary artery were from heart transplant patients. Left internal mammary artery (LIMA), saphenous vein and atrial appendage were from coronary artery bypass graft surgery patients. Samples of kidney, lung and adrenal gland were from histologically normal regions obtained following excision of tumors. For immunohistochemistry tissue was snap frozen in liquid nitrogen and stored at À 70 -C, for in vitro pharmacology tissue was collected in Krebs' solution (4 -C) and transported to the laboratory. Human umbilical vein endothelial cells (HUVECs) were cultured as described previously [34] , grown to subconfluency in 24 well plates and stored at À 70 -C (used at passage 2 -3).
Immunocytochemistry
Immunocytochemistry was carried out as described previously [34] . Briefly, fixed cryostat tissue sections, blocked with non-immunized swine serum, were incubated with rabbit-anti-human ghrelin antiserum (1 : 300 dilution, 48 h, 4 -C, Phoenix Pharmaceuticals, Belmont, CA, USA) or rabbit-anti-human ghrelin receptor antiserum (1 : 500 dilution, 96 h, 4 -C, Phoenix Pharmaceuticals). In adjacent sections, primary antisera were omitted or primary rabbit anti-ghrelin antiserum was pre-absorbed with ghrelin peptide (1 AM, Peptide Institute, Osaka, Japan) as negative controls. Staining was visualized using the peroxidase antiperoxidase method. In sections of rat brain used as a positive control, ghrelin receptor-like immunoreactivity (LI) was detected in hypothalamic neurons as previously described [35] (rat and human GHS-R1a show 96% amino acid sequence homology [36] ) (Fig. 2f ).
Fluorescent double staining and confocal microscopy
Fluorescent double staining was carried out as described previously [34] . Fixed sections or HUVECs in 24 well plates were blocked with goat serum, followed by incubation with rabbit-anti-human ghrelin antiserum (1 : 100 dilution) and mouse-anti-van Willebrand factor (vWF) monoclonal antibody (1 : 50 dilution) or mouse-anti-calnexin antibody (1 : 200)(24 h, 4 -C). Adjacent sections or wells were incubated with rabbit-anti-human ghrelin receptor antiserum (1 : 100 dilution) and mouse-anti-vWF (1 : 50 dilution), mouse-anti-smooth muscle a-actin monoclonal antibody (1 : 100 dilution) or mouse-anti-calnexin antibody (1 : 200)(24 h, 4 -C). Specific staining was visualized with fluorescent secondary antibodies and sections were mounted using medium containing 4V,6V-diamino-2-phenylindole hydrochloride (DAPI, Vector Laboratories, Burlingame, CA, USA) as a marker of cell nuclei. Confocal imaging was performed using a confocal laser-scanning microscope (Leica Microsystems, Heidelberg, Germany). Deconvolution was carried out using Huygens maximum likelihood estimation image restoration (Scientific Volume Imaging BV, The Netherlands).
In vitro pharmacology
2.4.1. Reversal of ET-1 constriction in LIMA Endothelium denuded rings (4 mm) of LIMA were mounted in 5 ml baths containing oxygenated Krebs' solution (mM: NaCl, 90; NaHCO 3 , 45; KCl, 5; MgSO 4 I7H 2 O, 0.5; Na 2 HPO 4 I2H 2 O, 1; CaCl 2 , 2.25; fumaric acid, 5; glutamic acid, 5; glucose, 10; sodium pyruvate, 5; pH 7.4; gassed with 95% O 2 /5% CO 2 at 37 -C) for the measurement of isometric force development and experiments were carried out as described previously [15] . Optimum resting tension was determined by repeated application of 0.1 M KCl at increasing levels of basal tension until no further increase in developed isometric force was obtained. Successful removal of functional endothelium was confirmed by showing the absence of a vasodilator response to 1 AM acetylcholine after preconstriction with 1 AM phenylephrine. Vessels were washed with fresh Krebs' containing G-nitro-l-arginine-methyl ester (l-NAME, 300 AM) and indomethacin (5 AM) (Sigma-Aldrich, Poole, UK) to exclude the possibility of endothelium dependent vasodilatation and after a 1 h equilibration period artery rings were pre-constricted with ET-1 (10 nM). Cumulative concentration-response curves to ghrelin and des-octanoyl ghrelin (Phoenix Pharmaceuticals) (0.1 -300 nM) were constructed. Experiments were terminated by addition of atrial natriuretic peptide (ANP, 10 nM) followed by S-nitroso-N-acetylpenicillamine (SNAP, 10 AM) (Sigma-Aldrich, Poole, UK) to determine maximal receptor mediated and receptor-independent vasodilatation. Adjacent ET-1 pre-constricted rings, with no ghrelin peptides added, served as time-matched controls. Vasodilator responses were expressed as percentage reversal of the ET-1 constriction and the negative logarithm of the EC 50 value (pD 2 ) and the maximum response (E max ) were determined using iterative curve fitting software (FigP, Biosoft, Cambs, UK).
Ghrelin actions in human paced atria
Human atrial appendages were cut into 3-4 mm strips parallel to atrial trabecular muscle bundles and set up in 10 ml organ baths containing oxygenated Krebs' solution for isometric tension recordings as described before [37] . After a 1 h equilibration period, atrial strips were paced using field stimulation (1 Hz square-wave pulse of 5 ms duration, voltage just above threshold (< 4.0 V) and set to optimum resting tension by increasing basal tension until no further increase in developed tension was observed. Tissue strips were adjusted to 50% of optimum resting tension and left to equilibrate for 30 min. Cumulative concentration-response curves were constructed to ghrelin and des-octanoyl ghrelin (0.1 -300 nM). Experiments were terminated by adding isoprenaline (0.2 mM, Sigma-Aldrich) followed by CaCl 2 (6.7 mM) to determine maximal h 1 -adrenoceptor-mediated and external Ca 2+ -mediated inotropic responses.
Statistical analysis
E max and pD 2 for ghrelin and des-octanoyl ghrelin were expressed as mean T standard error of the mean (SEM) and compared using Student's paired two-tailed t-test. A P-value < 0.05 was considered statistically significant.
Results
Immunocytochemistry
Ghrelin peptide
In human atrial and ventricular myocardium (n = 13) ghrelin-LI was detected in endothelial cells lining small intramyocardial blood vessels (Fig. 1a,f) , small coronary arteries and endocardial endothelial cells lining the recesses of the atrial chamber (Fig. 1b) . In atrial and ventricular cardiomyocytes, vascular smooth muscle cells and coronary adipocytes ghrelin-LI was absent or below the level of detection. In lung (n = 4), ghrelin-LI was restricted to endothelial cells of small pulmonary vessels, with no ghrelin-LI detected in vascular smooth muscle of pulmonary vessels, pulmonary epithelium or connective tissue. In kidney (n = 4) ghrelin-LI was present in endothelial cells lining small intrarenal vessels, but not in vascular smooth muscle cells, glomeruli, renal tubular epithelial cells or connective tissue (data not shown). In human large conduit vessels (n = 4 -6) we observed ghrelin-LI in endothelial cells lining saphenous vein (Fig.  1c) , coronary artery (Fig. 1d) and LIMA (Fig. 1e) but not in vascular smooth muscle cells forming the media. Staining was absent in sections where the primary antiserum was omitted and in sections incubated with ghrelin pre-absorbed antiserum (Fig. 1g) .
Ghrelin receptor
Ghrelin receptor-LI was present in human small intramyocardial (Fig. 2a,c) , pulmonary, renal and adrenal blood vessels, but absent or below the level of detection in epithelial cells, nerves or connective tissue. Ghrelin receptor-LI was detected in endothelial cells lining saphenous vein (Fig. 2d), LIMA (Fig. 2e) and coronary artery. Ghrelin receptor-LI was also expressed in the tunica media of saphenous vein (Fig. 2d), LIMA (Fig. 2e) and coronary artery. Low levels of ghrelin receptor-LI were observed in both the atrial and ventricular myocardium. Staining was absent in sections where the primary antiserum was omitted as a negative control (Fig. 2b,g ). Representative photomicrographs show ghrelin receptor-LI in vessels from the left ventricle (a, c). In human large conduit vessels ghrelin receptor-LI was expressed in endothelial cells lining large conduit vessels such as the saphenous vein (d) and internal mammary artery (e). Lower levels of ghrelin receptor-LI were detected in the tunica media of large conduit vessels including saphenous vein (d) and internal mammary artery (e). Photomicrograph (f) shows ghrelin receptor-LI in hypothalamic neurons in rat brain sections used as positive controls. In tissue sections where the primary antibody was omitted no ghrelin receptor-LI was detected (b, g). Scale bar = 100 Am. 
Fluorescent double staining and confocal microscopy 3.2.1. Ghrelin peptide
Confocal laser scanning microscopy detected ghrelin-LI and vWF-LI in the cytoplasm of endothelial cells from human large conduit, coronary and intramyocardial vessels. Within the endothelial cell cytoplasm ghrelin-LI was present in sub-cellular compartments of 1-5 Am in diameter (Fig.  3a -d) . To further investigate the sub-cellular distribution of ghrelin-LI, staining was carried out in HUVECs: Ghrelin-LI localized to vesicle-like structures (diameter < 1 Am) within the cytoplasm and to structures of¨5 Am diameter localized close to the cell nucleus (Fig. 4a,c) . Ghrelin-LI in vesiclelike structures partly colocalized with the endoplasmic reticulum marker calnexin (Fig. 4f) . Ghrelin-LI did not colocalize with vWF-LI in rod-like structures of the endothelial cell cytoplasm (Fig. 4c). 
Ghrelin receptor
In human myocardium, confocal microscopy detected intense staining for ghrelin receptor-LI on the cell surface of atrial and ventricular cardiomyocytes showing a transversal striated pattern (Fig. 3e -h ). Intense staining for ghrelin receptor-LI was present in vascular smooth muscle of intramyocardial blood vessels (Fig. 3i-p) , peripheral small resistance and large conduit vessels including LIMA (Fig.   Fig. 3 . Representative photomicrographs show confocal images of fluorescent double staining for ghrelin and vWF (a -d), ghrelin receptor (GR) and the smooth muscle marker a-actin (SMaA) (e -h, m -p and q -t) and ghrelin receptor and the endothelial marker vWF (i -l). DAPI is used as a marker for the cell nucleus. The first row shows single optical sections, rows 2 -5 show maximum intensity overlays of optical sections acquired over a range of¨20 Am. Ghrelin-LI is present in coronary artery endothelial cells (a -d). Ghrelin receptor-LI was detected in cardiomyocytes (e -h), coronary artery endothelial cells (i -l) and vascular smooth muscle cells of coronary artery (m -p) and internal mammary artery (q -t). Scale bar = 10 Am. 3q -t). Lower levels of ghrelin receptor-LI were present in vWF-positive vascular endothelial cells (Fig. 3i -p) . In HUVECs ghrelin receptor-LI localized to vesicle-like structures (< 1 Am) (Fig. 4g,i ) and partly colocalized with calnexin-LI. Ghrelin-LI did not colocalize with vWF-LI in rod-like structures of the endothelial cell cytoplasm (Fig. 4i) .
In vitro pharmacology
Reversal of ET-1 constriction in LIMA
Ghrelin reversed ET-1-induced vasoconstriction with a pD 2 = 8.6 T 0.1 and an E max = 55.8 T 8.9% in mammary artery from five patients (one female, four males, mean age 67 T 5 years) (Fig. 5a) . In adjacent vessels rings obtained from the same patient, des-octanoyl ghrelin reversed ET-1 induced vasoconstriction with a comparable pD 2 (8.8 T 0.2, n = 5, P = 0.5 vs. ghrelin) and E max (54.7 T 5.3%, n = 5, P = 0.9 vs. ghrelin) (Fig. 5b) . There was no significant difference ( P > 0.05) between basal resting tension (11.5 T 1.9 vs. 14.8 T 2.6 mN/mm), isometric force developed to 0.1 M KCl (14.0 T 1.8 vs. 11.3 T 2.5 mN/mm), isometric force developed to 10 nM ET-1 (9.3 T 1.5 vs. 7.0 + 1.1 mN/mm) and percentage reversal of ET-1 pre-constriction by 10 nM ANP (111.9 T 11.1 vs. 112.8 T 15.2%) and 10 AM SNAP (150.4 T 14.9 vs. 171.5 T 29.1%) in vessel rings treated with ghrelin or des-octanoyl ghrelin.
Ghrelin actions in human paced atria
In adjacent human isolated paced atria strips from six patients (six males, mean age 63 T 6 years), mean contractile force at optimum resting tension (7.4 T 1.9 mN) was increased to 12.5 T 3.4 mN in the presence of 0.2 mM isoprenaline. In the same tissues no response was observed to ghrelin or desoctanoyl ghrelin at concentrations up to 300 nM.
Discussion
In this study we show for the first time expression of ghrelin in endothelial cells of human arteries and veins and in secretory vesicles of cultured endothelial cells using immunocytochemistry. We report ghrelin receptor staining in human endothelial cells, vascular smooth muscle cells and cardiomyocytes and demonstrate vasoactive properties for des-octanoyl ghrelin in human isolated artery. Ghrelin and des-octanoyl ghrelin show comparable endothelium independent vasodilator potency and efficacy. Neither ghrelin nor des-octanoyl ghrelin had any effect on contractile force in human atria.
Our results showing ghrelin-LI in vascular and endocardial endothelial cells are consistent with the expression of ghrelin mRNA in HUVECs [38] and the detection of small amounts of ghrelin-LI in homogenates of rat and mouse heart and rat aorta using specific ghrelin radioimmunoassays (RIA) [39, 40] . Ubiquitous expression of ghrelin peptide in endothelial cells may explain the widespread distribution of low levels of ghrelin mRNA reported in all human tissues examined [5] . Immunocytochemical localization of ghrelin receptors in human cardiomyocytes, vascular smooth muscle cells and endothelial cells from different vascular beds substantiates reports showing low levels of ghrelin receptor mRNA in peripheral human tissues with highest levels detected in myocardium [41, 42] and corroborates observation of [ 125 I-His 9 ]-ghrelin binding in human heart and blood vessels [19] . The discovery of equipotent endothelium independent vasodilator actions for ghrelin and des-octanoyl ghrelin in isolated human artery is in agreement with previously reported vasodilator effects for ghrelin [15] . This provides evidence for biological activity of both octanoylated and non-octanoylated ghrelin in the human cardiovascular system which so far has only been reported in animals [27, 28, 43] .
Ubiquitous expression of ghrelin-LI in human endothelial cells supports a role for ghrelin as a paracrine cardiovascular mediator acting on ghrelin receptors present on vascular smooth muscle cells, endothelial cells and cardiomyocytes. Such a paracrine circuit may explain how a gastric peptide hormone with plasma levels fluctuating according to nutritional status [4] could be involved in the continuous regulation of blood pressure and cardiac performance. In the cytoplasm of endothelial cells ghrelin is present in secretory vesicles and shows partial colocalization with the endoplasmic reticulum marker calnexin. Ghrelin does however not colocalize with vWF positive Weibel -Palade bodies of the inducible pathway of peptide release, suggesting a constitutive pathway for ghrelin synthesis [33] . Constitutive ghrelin synthesis could be modulated at the transcriptional level by changes in circulating ghrelin levels that act via endothelial ghrelin receptors to form a negative feedback loop. We detected ghrelin receptors on cardiomyocytes ( Fig. 4a-d ) but did not observe inotropic actions of ghrelin in vitro. However, ghrelin shows long-term effects on cardiac performance [44] that may be mediated by ghrelin activating receptors that we have demonstrated on atrial and ventricular cardiomyocytes. An alternative explanation for the positive long-term effects of ghrelin on cardiac performance would be a reduction in cardiac afterload resulting from ghrelin-induced hypotensive actions.
In humans, des-octanoyl ghrelin is the predominant circulating form of the peptide [31, 39, 45] which, until recently, was considered biologically inactive [2, 46] . However, increasing evidence suggests biological actions for desoctanoyl ghrelin in the cardiovascular system [27, 28, 43] . In agreement we report equally potent and efficacious endothelium independent vasodilator actions for ghrelin and desoctanoyl ghrelin in human arteries, comparable to those observed for other established vasodilator peptides ( Table 1) . The ghrelin receptor-LI we observed in human large conduit vessels, including internal mammary arteries, suggests that the vasodilator responses to both peptides are mediated via the ghrelin receptor or a structurally related subtype. Neither ghrelin nor des-octanoyl ghrelin induced inotropic actions in isolated human paced atria, indicating that potential drug candidates acting on ghrelin receptors to lower blood pressure would benefit from a reduced risk of causing cardiac arrhythmia [47] . The vasoactive properties of ghrelin peptides and the tissue distribution of ghrelin receptor and ligand reported in this paper suggest a role as an emerging paracrine cardiovascular transmitter system mediating direct cardiovascular actions distinct from GH-dependent cardiovascular ghrelin effects [13] . The discovery of vascular responses to desoctanoyl ghrelin gives new perspective to the relative physiological importance of the ghrelin peptides in cardiovascular regulation, as total circulating ghrelin levels (octanoyl and des-octanoyl) are more than 10 times higher compared to levels of octanoylated peptide alone [31, 32, 39] . Des-octanoyl ghrelin does not show central effects on orexigenic pathways and GH release [2, 48] and the ghrelin receptor, as a class 1 GPCR, is potentially tractable as a target for small molecule agonists. Thus the hypotensive actions of des-octanoyl ghrelin may indicate the possibility to design drugs with selective vascular activity avoiding unwanted effects on the CNS ghrelin receptor. It is interesting to speculate whether the cardiovascular transmitter ghrelin could provide a link between obesity and major cardiovascular co-morbidities such as hypertension, atherosclerosis and heart disease. Obese individuals, similar to carriers of a rare ghrelin gene mutation, show decreased ghrelin plasma levels and are hypertensive [23, 49, 50] . Endothelial dysfunction, often seen in the obesity associated metabolic syndrome, could result in impaired paracrine endothelial ghrelin synthesis [51] leading to an additional reduction in the hypotensive ghrelin actions. We have demonstrated that ghrelin potently reverses ET-1 induced vasoconstriction, a peptide that is up regulated in atherosclerosis, suggesting that the ghrelin system is a promising candidate for cardiovascular drug discovery.
